title: Effect of treatment on the rate of visual field change in the ocular hypertension treatment study observation group.
abstract: OBJECTIVE
  The goal in this study was to compare rates of visual field (VF) change before and after the initiation of treatment in participants originally randomized to the observation arm of the Ocular Hypertension Treatment Study (OHTS).
  
  
  METHODS
  We included OHTS participants originally randomized to observation and excluded those who reached non-POAG endpoints. VF progression was determined using trend analysis. Global and localized rates of VF change were calculated based on linear regression over time of mean deviation (MD) and threshold sensitivity values for each test location. MD rates (MDR) and pointwise linear regression (PLR) analysis were also assessed using six VF tests before and after the initiation of treatment. A PLR endpoint was defined as a VF test location progressing faster than -0.5 dB/year at P < 0.01.
  
  
  RESULTS
  We included 780 eyes from 432 OHTS participants. Following the initiation of treatment, the mean MDR decreased from -0.23 ± 0.6 to -0.06 ± 0.5 dB/year (P < 0.01) and the number of VF locations reaching a PLR endpoint decreased from 2.13 ± 6.0 to 1.00 ± 4.0 (P < 0.01). The benefit of treatment was significant both among participants who did not convert (-0.17 ± 0.6 vs. -0.01 ± 0.5 dB/year, P < 0.01) and among those who converted to glaucoma (-0.51 ± 0.8 vs. -0.27 ± 0.7 dB/year, P < 0.01) based on the OHTS event-based endpoint.
  
  
  CONCLUSIONS
  The initiation of ocular hypotensive medication among OHTS participants originally randomized to observation significantly reduced the velocity of VF progression.
authors.affiliation: Einhorn Clinical Research Center, New York Eye and Ear Infirmary, New York, NY 10003, USA. demoraesmd@gmail.com
authors.forename: Carlos Gustavo
authors.initials: CG
authors.lastname: De Moraes
authors.forename: Shaban
authors.initials: S
authors.lastname: Demirel
authors.forename: Stuart K
authors.initials: SK
authors.lastname: Gardiner
authors.forename: Jeffrey M
authors.initials: JM
authors.lastname: Liebmann
authors.forename: George A
authors.initials: GA
authors.lastname: Cioffi
authors.forename: Robert
authors.initials: R
authors.lastname: Ritch
authors.forename: Mae O
authors.initials: MO
authors.lastname: Gordon
authors.forename: Michael A
authors.initials: MA
authors.lastname: Kass
mesh_terms: D000287:Administration, Topical; D000959:Antihypertensive Agents / Q000008:administration & dosage*; D018450:Disease Progression; D005902:Glaucoma, Open-Angle / Q000175:diagnosis / Q000503:physiopathology*; D006801:Humans; D015994:Incidence; D007429:Intraocular Pressure / Q000187:drug effects; D019370:Observation; D009798:Ocular Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D014786:Vision Disorders / Q000175:diagnosis / Q000503:physiopathology*; D058609:Visual Field Tests; D014794:Visual Fields / Q000502:physiology*
chemical_list: D000959:Antihypertensive Agents